– UK, London – Foxtons Group PLC (LON: FOXT) today announced the appointment of Alan Giles as a non-executive Director of the Company with effect from 1 June 2019. Alan will be a member of the Remuneration, Audit and Nomination Committees.
Garry Watts, Chairman of Foxtons, said: “Alan has a distinguished and highly relevant background. His experience and skills will be a significant addition to Foxtons. I and my colleagues greatly look forward to working with him.”
About Alan Giles
Mr Giles has extensive experience as a non-executive director and is currently the senior independent non-executive director of Perpetual Income and Growth Investment Trust plc. He is also the Chairman of The Remuneration Consultants Group, an associate fellow of Saïd Business School, University of Oxford, and an honorary visiting professor at Cass Business School, City, University of London.
Mr Giles was the senior independent non-executive director and chairman of the remuneration committee of Rentokil Initial plc until May 2017, and the senior independent non-executive board member and remuneration committee chairman of The Competition and Markets Authority until March 2019. He was formerly chairman of Fat Face Group Limited, chief executive of HMV Group Plc, managing director of Waterstones, and an executive director of WH Smith Plc, and he previously held non-executive directorships at The Office of Fair Trading, Somerfield Plc, and Wilson Bowden Plc.
Alan Giles said: “I am delighted to be joining Foxtons, which is a well-differentiated brand with a strong market position. I am looking forward to working with the Board and management team.”
For more information: https://www.foxtons.co.uk
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
Comments are closed.